We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GE HealthCare to Post Q1 Earnings: What's in Store for the Stock?
Read MoreHide Full Article
Key Takeaways
GE HealthCare to report Q1 on April 29, with backlog likely supporting low- to mid-single-digit growth.
GE HealthCare sees strength in Pharma Diagnostics, Imaging, and AVS driving performance.
GE HealthCare faces China weakness, tariff pressure, and mixed Patient Care results.
GE HealthCare Technologies Inc. (GEHC - Free Report) is scheduled to report first-quarter 2026 results on April 29, before market open.
In the last reported quarter, the company’s adjusted earnings per share (EPS) of $1.44 surpassed the Zacks Consensus Estimate by 0.70%. The company beat on earnings in each of the trailing four quarters, delivering an average surprise of 7.52%.
Let’s check out the factors that might have shaped GEHC’s performance prior to the announcement.
GE HealthCare Technologies Inc. Price and EPS Surprise
Factors Likely to Have Driven GEHC’s Q1 Performance
GE HealthCare Technologies’ quarterly results are expected to reflect steady underlying demand, supported by robust developed-market trends and continued momentum in its high-growth Pharmaceutical Diagnostics business.
Following a solid exit to 2025, the company is likely to have sustained low- to mid-single-digit organic revenue growth in the first quarter, supported by a record $21.8 billion backlog that continues to provide revenue visibility. However, this growth may have been partially offset by ongoing weakness in China and the delayed commercial impact of recently launched products awaiting regulatory approval.
At the margin level, profitability is likely to have remained under pressure. While management has executed supply-chain adjustments and productivity initiatives through its “Heartbeat” program, tariff-related costs (previously a significant headwind) are likely to have continued to weigh on earnings, albeit at a moderating pace.
Across segments, Imaging is expected to have delivered stable growth, driven by healthy demand in the U.S. and EMEA markets, particularly in nuclear medicine. However, margins in the segment are likely to have remained under pressure due to tariffs and mix. Advanced Visualization Solutions should have maintained mid-single-digit growth, supported by strong adoption of newer platforms, such as Vivid Pioneer and continued demand across cardiovascular and women’s health.
Patient Care Solutions is likely to reflect sequential improvement following earlier shipment disruptions, although year-over-year performance might have remained muted due to weakness in Life Support Solutions and unfavorable mix dynamics.
Pharmaceutical Diagnostics is expected to have led overall growth, supported by robust demand for contrast media and increasing adoption of radiopharmaceuticals. While Flyrcado remains in the early stages of commercialization, improving delivery consistency and gradual customer onboarding suggest a growing contribution.
GEHC’s Estimate Picture
For first-quarter 2026, the Zacks Consensus Estimate for revenues is pegged at $5.05 billion, implying an improvement of 5.8% from the prior-year quarter’s reported figure.
The consensus estimate for EPS is pegged at $1.07, indicating an increase of 5.9% from the prior-year period’s reported number.
What Our Model Suggests for GE HealthCare
Per our proven model, the combination of a positive Earnings ESPand a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. That is not the case here, as you will see below.
Earnings ESP: GE HealthCare has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
So far this year, GE HealthCare’s shares have lost 13% compared with the industry’s 17.1% decline. The S&P 500 has gained 3.2% during the period.
Image Source: Zacks Investment Research
Stocks Worth a Look
Here are some medical product stocks worth considering as these have the right combination of elements to post an earnings beat this reporting cycle.
Henry Schein (HSIC - Free Report) has an Earnings ESP of +0.28% and a Zacks Rank #3 at present.
HSIC’s earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 2.14%. The Zacks Consensus Estimate for HSIC’s first-quarter EPS indicates an improvement of 4.4% from the year-ago reported figure.
Thermo Fisher Scientific (TMO - Free Report) has an Earnings ESP of +0.95% and a Zacks Rank of 3 at present. The company is set to release first-quarter fiscal 2026 results on April 23.
TMO’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 2.78%. The Zacks Consensus Estimate for TMO’s first-quarter EPS implies an improvement of 1% from the year-ago reported figure.
IDEXX Laboratories (IDXX - Free Report) has an Earnings ESP of +0.77% and a Zacks Rank of 3 at present. The company is slated to release first-quarter 2026 results on May 5.
IDXX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.11%. The Zacks Consensus Estimate for IDXX’s first-quarter EPS calls for a gain 15.5% from the year-ago reported figure.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Shutterstock
GE HealthCare to Post Q1 Earnings: What's in Store for the Stock?
Key Takeaways
GE HealthCare Technologies Inc. (GEHC - Free Report) is scheduled to report first-quarter 2026 results on April 29, before market open.
In the last reported quarter, the company’s adjusted earnings per share (EPS) of $1.44 surpassed the Zacks Consensus Estimate by 0.70%. The company beat on earnings in each of the trailing four quarters, delivering an average surprise of 7.52%.
Let’s check out the factors that might have shaped GEHC’s performance prior to the announcement.
GE HealthCare Technologies Inc. Price and EPS Surprise
GE HealthCare Technologies Inc. price-eps-surprise | GE HealthCare Technologies Inc. Quote
Factors Likely to Have Driven GEHC’s Q1 Performance
GE HealthCare Technologies’ quarterly results are expected to reflect steady underlying demand, supported by robust developed-market trends and continued momentum in its high-growth Pharmaceutical Diagnostics business.
Following a solid exit to 2025, the company is likely to have sustained low- to mid-single-digit organic revenue growth in the first quarter, supported by a record $21.8 billion backlog that continues to provide revenue visibility. However, this growth may have been partially offset by ongoing weakness in China and the delayed commercial impact of recently launched products awaiting regulatory approval.
At the margin level, profitability is likely to have remained under pressure. While management has executed supply-chain adjustments and productivity initiatives through its “Heartbeat” program, tariff-related costs (previously a significant headwind) are likely to have continued to weigh on earnings, albeit at a moderating pace.
Across segments, Imaging is expected to have delivered stable growth, driven by healthy demand in the U.S. and EMEA markets, particularly in nuclear medicine. However, margins in the segment are likely to have remained under pressure due to tariffs and mix. Advanced Visualization Solutions should have maintained mid-single-digit growth, supported by strong adoption of newer platforms, such as Vivid Pioneer and continued demand across cardiovascular and women’s health.
Patient Care Solutions is likely to reflect sequential improvement following earlier shipment disruptions, although year-over-year performance might have remained muted due to weakness in Life Support Solutions and unfavorable mix dynamics.
Pharmaceutical Diagnostics is expected to have led overall growth, supported by robust demand for contrast media and increasing adoption of radiopharmaceuticals. While Flyrcado remains in the early stages of commercialization, improving delivery consistency and gradual customer onboarding suggest a growing contribution.
GEHC’s Estimate Picture
For first-quarter 2026, the Zacks Consensus Estimate for revenues is pegged at $5.05 billion, implying an improvement of 5.8% from the prior-year quarter’s reported figure.
The consensus estimate for EPS is pegged at $1.07, indicating an increase of 5.9% from the prior-year period’s reported number.
What Our Model Suggests for GE HealthCare
Per our proven model, the combination of a positive Earnings ESPand a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. That is not the case here, as you will see below.
Earnings ESP: GE HealthCare has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
GEHC’s Share Price Performance
So far this year, GE HealthCare’s shares have lost 13% compared with the industry’s 17.1% decline. The S&P 500 has gained 3.2% during the period.
Image Source: Zacks Investment Research
Stocks Worth a Look
Here are some medical product stocks worth considering as these have the right combination of elements to post an earnings beat this reporting cycle.
Henry Schein (HSIC - Free Report) has an Earnings ESP of +0.28% and a Zacks Rank #3 at present.
HSIC’s earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 2.14%. The Zacks Consensus Estimate for HSIC’s first-quarter EPS indicates an improvement of 4.4% from the year-ago reported figure.
Thermo Fisher Scientific (TMO - Free Report) has an Earnings ESP of +0.95% and a Zacks Rank of 3 at present. The company is set to release first-quarter fiscal 2026 results on April 23.
TMO’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 2.78%. The Zacks Consensus Estimate for TMO’s first-quarter EPS implies an improvement of 1% from the year-ago reported figure.
IDEXX Laboratories (IDXX - Free Report) has an Earnings ESP of +0.77% and a Zacks Rank of 3 at present. The company is slated to release first-quarter 2026 results on May 5.
IDXX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.11%. The Zacks Consensus Estimate for IDXX’s first-quarter EPS calls for a gain 15.5% from the year-ago reported figure.